August 2018, Volume 4, Issue 10

August 2018

Volume 4, Issue 10

This issue features a look at direct-to-consumer pharmaceutical advertising, advice to graduating hematologists, and more.

Table of Contents

August 2018 Issue

Caring About Standards of Care

Tuesday, July 31st, 2018
I’ve been thinking a lot about standards of care recently. A “medical standard of care” is actually a legal term, typically defined as the level...

A Slow Burn

Tuesday, July 31st, 2018
In our July 2018 issue, ASH Clinical News Associate Editor Keith Stewart, MBChB, MBA, walked us through his valiant efforts to step away from...

August 2018 Issue

Mehdi Hamadani Named Editor of ASH News Daily 2018, and more

Tuesday, July 31st, 2018
Mehdi Hamadani Named Editor of ASH News Daily 2018  Mehdi Hamadani, MD, has been named the 2018 Editor-in- Chief of ASH News Daily, the official...

Fred Hutch Scientists Receive $20 Million for Leukemia Projects, and more

Tuesday, July 31st, 2018
Remembering Alan Rabson (1926 – 2018)Alan Rabson, MD, a long-time leader at the National Cancer Institute (NCI), passed away on July 4, 2018, at...

August 2018 Issue

Pulling Back the Curtain: Angela Thomas, OBE, PhD

Tuesday, July 31st, 2018
In this edition, Angela Thomas, OBE, PhD, talks about defying expectations and mixing politics and medicine. In Sound Bites, hear more from our interview with...

Ad Nauseam

Tuesday, July 31st, 2018
With new forays into sponsored content, pharmaceutical companies are rewriting the script for direct-to-consumer advertising.  When U.S. consumers settle in to watch their favorite TV...

August 2018 Issue

Is splenectomy a good option for a patient with hemoglobin H disease?

Tuesday, July 31st, 2018
This month Swee Lay Thein, MD, discusses the pros and cons of splenectomy for a patient with hemoglobin H disease. And don't forget to check...

Is splenectomy a good option for a patient with hemoglobin H disease?

Tuesday, July 31st, 2018
Here’s how readers responded to a You Make the Call question about performing a splenectomy on a patient with hemoglobin H disease who does...

August 2018 Issue

WIB_icon

Risk-Adapted, Chemotherapy-Alone Treatment Strategy Effective for Early-Stage Hodgkin Lymphoma

Tuesday, July 31st, 2018
Detection of disease on interim PET/CT scans after two cycles of chemotherapy is a powerful predictor of outcomes in patients with early-stage, non-bulky Hodgkin...

Venetoclax Approved for All Patients With Relapsed/Refractory CLL and SLL

Tuesday, July 31st, 2018
The U.S. Food and Drug Administration (FDA) granted approval to venetoclax for the treatment of patients with previously treated chronic lymphocytic leukemia (CLL) or...

Extended Analysis Shows Venetoclax Continues to Produce Deep Responses in CLL

Tuesday, July 31st, 2018
In 2016, the U.S. Food and Drug Administration granted venetoclax accelerated approval for the treatment of adults with previously treated chronic lymphocytic leukemia (CLL)...

Denosumab Versus Zoledronic Acid for Reducing Time to Skeletal Events in Multiple Myeloma

Tuesday, July 31st, 2018
Approximately 90 percent of patients diagnosed with multiple myeloma (MM) present with bone lesions and are typically treated with zoledronic acid (ZA), a potentially...

AMA Announces New Approach to Physician Mental Health Care

Tuesday, July 31st, 2018
In response to growing concerns about the mental health of physicians and medical students, the American Medical Association (AMA) has adopted a new policy...

FDA Approves Pembrolizumab for Relapsed/Refractory PMBCL

Tuesday, July 31st, 2018
Pembrolizumab was granted an accelerated approval by the U.S. Food and Drug Administration (FDA) for the treatment of adult and pediatric patients with refractory...
WIB_icon

Observation Versus Immunoglobulin Therapy in Children With Chronic ITP

Tuesday, July 31st, 2018
Compared with observation, treatment with intravenous immunoglobulin (IVIg) did not prevent the risk of developing chronic immune thrombocytopenia purpura (ITP) in children newly diagnosed...

Drug Shortages Rising Again After Five Years

Tuesday, July 31st, 2018
For the past five years, the number of new drug shortages reported to the U.S. Food and Drug Administration (FDA) was declining steadily. However,...

Lenalidomide Therapy Increases VTE Risk in B-Cell Non-Hodgkin Lymphoma

Tuesday, July 31st, 2018
Patients with B-cell non-Hodgkin lymphoma (NHL) treated with lenalidomide have an increased risk of developing venous thromboembolism (VTE) – similar to the increased risk...

Ibrutinib and Venetoclax Combo Confers High Response in Mantle-Cell Lymphoma

Tuesday, July 31st, 2018
In results from a phase II study published in The New England Journal of Medicine, the combination of the Bruton tyrosine kinase (BTK) inhibitor...

Adding Carfilzomib to Lenalidomide and Dexamethasone Extends Overall Survival in Multiple Myeloma

Tuesday, July 31st, 2018
Compared with standard therapy of lenalidomide and dexamethasone, the addition of carfilzomib improved survival, without increasing the risk of adverse events (AEs) in patients...

August 2018 Issue

CheckMate 205: Evaluating Nivolumab in Newly Diagnosed Hodgkin Lymphoma

Tuesday, July 31st, 2018
In a study presented by Radhakrishnan Ramchandren, MD, at the 23rd Congress of the European Hematology Association, the four-drug regimen of nivolumab plus doxorubicin,...

Better Together: IDH Inhibitors Plus Azacitidine in Newly Diagnosed AML

Tuesday, July 31st, 2018
Results from a phase Ib/II study presented at the 23rd Congress of the European Hematology Association suggest that combining an IDH inhibitor (ivosidenib or...

Cardiac Biomarkers Predict Quality of Life in Patients With Light-Chain Amyloidosis

Tuesday, July 31st, 2018
In a study presented at the 23rd Congress of the European Hematology Association, researchers demonstrated a relationship between B-type natriuretic peptide (BNP) and N-terminal...

Bispecific Antibody AMV564 Active in Relapsed and Refractory AML

Tuesday, July 31st, 2018
Treatment with the CD33/CD3 bivalent, bispecific antibody AMV564 demonstrated clinical activity in patients with relapsed and refractory acute myeloid leukemia (AML) with a tolerable...

Combining Ibrutinib and Venetoclax Produces High MRD-Negative Rates in Treatment-Naïve CLL

Tuesday, July 31st, 2018
The all-oral regimen of single-agent ibrutinib followed by combined ibrutinib and venetoclax increased the odds that patients with treatment-naïve chronic lymphocytic leukemia (CLL) will...

Updated Results from JULIET: Tisagenlecleucel Associated With Durable Responses in DLBCL

Tuesday, July 31st, 2018
In May 2018, the U.S. Food and Drug Administration expanded the approval of the chimeric antigen receptor (CAR) T-cell therapy tisagenlecleucel to the treatment...

Obinutuzumab Beats Rituximab in Older Patients With CLL

Tuesday, July 31st, 2018
Treatment with obinutuzumab plus chlorambucil led to greater improvements in progression-free survival (PFS) and overall survival (OS) than the combination of rituximab and chlorambucil,...

Higher-Dose Daunorubicin No More Effective Than Lower Doses in AML

Tuesday, July 31st, 2018
Escalating daunorubicin doses from 60 mg/m2 to 90 mg/m2 in a 7+3 induction regimen consisting of daunorubicin and cytarabine did not increase response rates...

SHARE